Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma

Enrico Battolla, Pier Aldo Canessa, Paola Ferro, Maria Cristiana Franceschini, Vincenzo Fontana, Paolo Dessanti, Valentina Pinelli, Anna Morabito, Franco Fedeli, Maria Pia Pistillo, Silvio Roncella

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: In the literature, there exist conflicting data on the value of fibulin-3 (FBLN3) for the diagnosis of pleural effusion (PE) in malignant pleural mesothelioma (MPM). Therefore we compared the diagnostic performance of FBLN3 against that of soluble mesothelinrelated peptide (SMRP) in a cohort of Italian patients. Materials and Methods: FBLN3 and SMRP were detected in PE from 33 patients with MPM, 64 with pleural benign lesions and 23 with non-MPM pleural metastases using a commercial enzyme-linked-immunosorbent(ELISA)-assay kit according to manufacturers' instructions. Results: Levels of FBLN3 were similar in PE from MPM and PE from other pathologies (geometric mean=68.1 vs. 66.2 ng/ml; p=0.872) in contrast to SMRP levels, which were significantly higher in PE from MPM (geometric mean=14.6 vs. 3.2 nM; p<0.001). Receiver operating characteristic analysis confirmed that SMRP showed a good performance (area under the curve=0.79, p<0.001), whereas FBLN3 was not able to discriminate MPM from other pathologies (area under the curve=0.44, p=0.838). Conclusion: FBLN3 detection in PE, in contrast to SMRP detection, is not useful as a biomarker for the diagnosis of PE from MPM.

Original languageEnglish
Pages (from-to)1387-1391
Number of pages5
JournalAnticancer Research
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Pleural Effusion
Peptides
Area Under Curve
Enzyme-Linked Immunosorbent Assay
Pathology
Mesothelioma
Malignant Mesothelioma
mesothelin
fibulin
ROC Curve
Biomarkers
Neoplasm Metastasis

Keywords

  • Fibulin-3
  • Malignant pleural mesothelioma
  • Mesothelin
  • Pleural effusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma. / Battolla, Enrico; Canessa, Pier Aldo; Ferro, Paola; Franceschini, Maria Cristiana; Fontana, Vincenzo; Dessanti, Paolo; Pinelli, Valentina; Morabito, Anna; Fedeli, Franco; Pistillo, Maria Pia; Roncella, Silvio.

In: Anticancer Research, Vol. 37, No. 3, 01.03.2017, p. 1387-1391.

Research output: Contribution to journalArticle

Battolla, E, Canessa, PA, Ferro, P, Franceschini, MC, Fontana, V, Dessanti, P, Pinelli, V, Morabito, A, Fedeli, F, Pistillo, MP & Roncella, S 2017, 'Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma', Anticancer Research, vol. 37, no. 3, pp. 1387-1391. https://doi.org/10.21873/anticanres.11460
Battolla, Enrico ; Canessa, Pier Aldo ; Ferro, Paola ; Franceschini, Maria Cristiana ; Fontana, Vincenzo ; Dessanti, Paolo ; Pinelli, Valentina ; Morabito, Anna ; Fedeli, Franco ; Pistillo, Maria Pia ; Roncella, Silvio. / Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma. In: Anticancer Research. 2017 ; Vol. 37, No. 3. pp. 1387-1391.
@article{fb35bacb26e94e71a050db7bef3f1e8c,
title = "Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma",
abstract = "Background: In the literature, there exist conflicting data on the value of fibulin-3 (FBLN3) for the diagnosis of pleural effusion (PE) in malignant pleural mesothelioma (MPM). Therefore we compared the diagnostic performance of FBLN3 against that of soluble mesothelinrelated peptide (SMRP) in a cohort of Italian patients. Materials and Methods: FBLN3 and SMRP were detected in PE from 33 patients with MPM, 64 with pleural benign lesions and 23 with non-MPM pleural metastases using a commercial enzyme-linked-immunosorbent(ELISA)-assay kit according to manufacturers' instructions. Results: Levels of FBLN3 were similar in PE from MPM and PE from other pathologies (geometric mean=68.1 vs. 66.2 ng/ml; p=0.872) in contrast to SMRP levels, which were significantly higher in PE from MPM (geometric mean=14.6 vs. 3.2 nM; p<0.001). Receiver operating characteristic analysis confirmed that SMRP showed a good performance (area under the curve=0.79, p<0.001), whereas FBLN3 was not able to discriminate MPM from other pathologies (area under the curve=0.44, p=0.838). Conclusion: FBLN3 detection in PE, in contrast to SMRP detection, is not useful as a biomarker for the diagnosis of PE from MPM.",
keywords = "Fibulin-3, Malignant pleural mesothelioma, Mesothelin, Pleural effusion",
author = "Enrico Battolla and Canessa, {Pier Aldo} and Paola Ferro and Franceschini, {Maria Cristiana} and Vincenzo Fontana and Paolo Dessanti and Valentina Pinelli and Anna Morabito and Franco Fedeli and Pistillo, {Maria Pia} and Silvio Roncella",
year = "2017",
month = "3",
day = "1",
doi = "10.21873/anticanres.11460",
language = "English",
volume = "37",
pages = "1387--1391",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma

AU - Battolla, Enrico

AU - Canessa, Pier Aldo

AU - Ferro, Paola

AU - Franceschini, Maria Cristiana

AU - Fontana, Vincenzo

AU - Dessanti, Paolo

AU - Pinelli, Valentina

AU - Morabito, Anna

AU - Fedeli, Franco

AU - Pistillo, Maria Pia

AU - Roncella, Silvio

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: In the literature, there exist conflicting data on the value of fibulin-3 (FBLN3) for the diagnosis of pleural effusion (PE) in malignant pleural mesothelioma (MPM). Therefore we compared the diagnostic performance of FBLN3 against that of soluble mesothelinrelated peptide (SMRP) in a cohort of Italian patients. Materials and Methods: FBLN3 and SMRP were detected in PE from 33 patients with MPM, 64 with pleural benign lesions and 23 with non-MPM pleural metastases using a commercial enzyme-linked-immunosorbent(ELISA)-assay kit according to manufacturers' instructions. Results: Levels of FBLN3 were similar in PE from MPM and PE from other pathologies (geometric mean=68.1 vs. 66.2 ng/ml; p=0.872) in contrast to SMRP levels, which were significantly higher in PE from MPM (geometric mean=14.6 vs. 3.2 nM; p<0.001). Receiver operating characteristic analysis confirmed that SMRP showed a good performance (area under the curve=0.79, p<0.001), whereas FBLN3 was not able to discriminate MPM from other pathologies (area under the curve=0.44, p=0.838). Conclusion: FBLN3 detection in PE, in contrast to SMRP detection, is not useful as a biomarker for the diagnosis of PE from MPM.

AB - Background: In the literature, there exist conflicting data on the value of fibulin-3 (FBLN3) for the diagnosis of pleural effusion (PE) in malignant pleural mesothelioma (MPM). Therefore we compared the diagnostic performance of FBLN3 against that of soluble mesothelinrelated peptide (SMRP) in a cohort of Italian patients. Materials and Methods: FBLN3 and SMRP were detected in PE from 33 patients with MPM, 64 with pleural benign lesions and 23 with non-MPM pleural metastases using a commercial enzyme-linked-immunosorbent(ELISA)-assay kit according to manufacturers' instructions. Results: Levels of FBLN3 were similar in PE from MPM and PE from other pathologies (geometric mean=68.1 vs. 66.2 ng/ml; p=0.872) in contrast to SMRP levels, which were significantly higher in PE from MPM (geometric mean=14.6 vs. 3.2 nM; p<0.001). Receiver operating characteristic analysis confirmed that SMRP showed a good performance (area under the curve=0.79, p<0.001), whereas FBLN3 was not able to discriminate MPM from other pathologies (area under the curve=0.44, p=0.838). Conclusion: FBLN3 detection in PE, in contrast to SMRP detection, is not useful as a biomarker for the diagnosis of PE from MPM.

KW - Fibulin-3

KW - Malignant pleural mesothelioma

KW - Mesothelin

KW - Pleural effusion

UR - http://www.scopus.com/inward/record.url?scp=85015898177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015898177&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11460

DO - 10.21873/anticanres.11460

M3 - Article

VL - 37

SP - 1387

EP - 1391

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -